Akèy › Lukemi lenfositè kwonik › Connecticut › New Haven
Etid klinik pou Lukemi lenfositè kwonik nan New Haven, CT
3 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote New Haven (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- Yale University Yale Cancer Center, New Haven
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Yale Cancer Center, New Haven
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 3
- Yale University School of Medicine /ID# 266224, New Haven
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Cincinnati, OH14 etid
Lòt etid nan New Haven
- Kansè Poumon ki pa ti selil41 etid
- Kansè nan tete37 etid
- Kansè (tout kalite)33 etid
- Kansè Metastatik23 etid
- Kansè poumon22 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
- Kansè ovè21 etid
- Kansè kolorektal20 etid
- Kansè pwostat20 etid
- Sòvdòz Opioyid18 etid
- Twoub Konsomasyon Alkòl (AUD)17 etid
- Leksemi mieloïd egi17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.